← Back to Screener
Edwards Lifesciences Corp (EW)
Price$85.96
Value ScoreD
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-8.74%
Price vs S&P 500 (4W)7.51%
VGM Score44.99
Market Capitalization$49.50B
P/E Ratio (Annual)46.11x
All Metrics
P/CF (Annual)31.03x
Book Value / Share (Quarterly)$17.90
P/TBV (Annual)5.37x
Revenue Growth (3Y)4.08%
Cash Flow / Share (Quarterly)$1.89
Price vs S&P 500 (YTD)-7.33%
Gross Margin (TTM)77.87%
Net Profit Margin (TTM)17.39%
EPS (TTM)$1.88
10-Day Avg Trading Volume6.02M
EPS Excl Extra (TTM)$1.88
Revenue Growth (5Y)6.70%
EPS (Annual)$1.83
ROI (Annual)9.82%
Gross Margin (Annual)78.01%
Net Profit Margin (5Y Avg)34.96%
Cash / Share (Quarterly)$6.36
P/E Basic Excl Extra (TTM)45.15x
Revenue Growth QoQ (YoY)16.70%
EPS Growth (5Y)7.06%
P/E Normalized (Annual)46.11x
ROA (Last FY)7.84%
Revenue Growth TTM (YoY)13.81%
EBITD / Share (TTM)$2.12
ROE (5Y Avg)25.04%
Operating Margin (TTM)17.08%
Cash Flow / Share (Annual)$2.30
P/B Ratio4.79x
P/B Ratio (Quarterly)4.47x
Net Income / Employee (Annual)$67,100
EV / Revenue (TTM)7.56x
Net Interest Coverage (TTM)3.15x
ROA (TTM)8.15%
EPS Growth QoQ (YoY)7.63%
EV / EBITDA (TTM)38.51x
EPS Incl Extra (Annual)$1.83
Current Ratio (Annual)3.72x
Quick Ratio (Quarterly)3.53x
3-Month Avg Trading Volume5.11M
52-Week Price Return10.53%
EV / Free Cash Flow (Annual)35.69x
P/E Incl Extra (TTM)45.15x
Revenue / Employee (TTM)$394,000
Tangible BV / Share (Quarterly)$15.77
P/S Ratio (Annual)8.16x
Asset Turnover (Annual)0.44x
52-Week High$89.48
Operating Margin (5Y Avg)25.36%
EPS Excl Extra (Annual)$1.83
CapEx CAGR (5Y)-8.57%
Tangible BV CAGR (5Y)16.76%
26-Week Price Return-0.82%
Quick Ratio (Annual)3.02x
13-Week Price Return2.47%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)4.42x
Enterprise Value$47.65B
Revenue / Share Growth (5Y)8.33%
Asset Turnover (TTM)0.47x
Book Value / Share Growth (5Y)19.43%
Revenue / Employee (Annual)$379,200
Inventory Turnover (Annual)1.21x
Pretax Margin (Annual)20.98%
Cash / Share (Annual)$7.28
3-Month Return Std Dev28.93%
Gross Margin (5Y Avg)74.05%
Net Income / Employee (TTM)$68,500
EBITDA CAGR (5Y)4.86%
EBITDA Interim CAGR (5Y)-1.03%
ROE (Last FY)10.38%
Net Interest Coverage (Annual)110.03x
EPS Basic Excl Extra (Annual)$1.83
P/FCF (TTM)37.08x
Receivables Turnover (TTM)8.73x
EV / Free Cash Flow (TTM)43.73x
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$1.88
Receivables Turnover (Annual)9.57x
ROI (TTM)10.01%
P/S Ratio (TTM)7.85x
Pretax Margin (5Y Avg)26.61%
Revenue / Share (Annual)$10.36
Tangible BV / Share (Annual)$15.86
Forward P/E28.54x
Free OCF CAGR (5Y)15.59%
Price vs S&P 500 (52W)-13.83%
P/E Ratio (TTM)45.15x
EPS Growth TTM (YoY)-73.20%
Year-to-Date Return0.83%
5-Day Price Return-2.50%
EPS Normalized (Annual)$1.83
ROA (5Y Avg)18.17%
Net Profit Margin (Annual)17.69%
Month-to-Date Return-0.59%
Cash Flow / Share (TTM)$2.57
EBITD / Share (Annual)$2.17
EPS Growth (3Y)-9.08%
Operating Margin (Annual)18.41%
LT Debt / Equity (Annual)0.06x
P/CF (TTM)36.43x
ROI (5Y Avg)23.14%
P/E Excl Extra (TTM)45.15x
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$1.88
P/TBV (Quarterly)5.07x
P/B Ratio (Annual)4.79x
Inventory Turnover (TTM)1.25x
Pretax Margin (TTM)20.59%
Book Value / Share (Annual)$17.80
Price vs S&P 500 (13W)-5.79%
Net Margin Growth (5Y)-1.18%
Beta0.84x
P/FCF (Annual)37.08x
Revenue / Share (TTM)$10.86
ROE (TTM)10.59%
52-Week Low$72.30
vGradeD
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.78est. 0.75
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.98
3.98
3.98
4.02
Industry Peers — Orthopedic & Prosthetic Devices(33)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EWEdwards Lifesciences Corp | D | C | C | $85.96 |
| ISRGIntuitive Surgical Inc. | F | B | C | $422.06 |
| STESTERIS plc | C | B | C | $212.35 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | C | $87.33 |
| ALGNAlign Technology Inc | B | C | C | $167.74 |
| SNNSmith & Nephew plc | B | C | C | $30.61 |
| MSAMine Safety Incorporated | B | C | C | $161.30 |
| ESTAEstablishment Labs Holdings Inc. | F | A | B | $74.31 |
| ENOVEnovis Corporation | B | D | C | $23.78 |
| CDRECadre Holdings, Inc. | C | C | D | $30.01 |
| AVNSAvanos Medical, Inc. | B | D | A | $25.05 |
About
Edwards Lifesciences is a global leader in medical devices for treating structural heart disease, specializing in surgical tissue heart valves and transcatheter valve replacement technologies. Spun off from Baxter International in 2000, the company has established dominant market positions across aortic, mitral, and tricuspid valve solutions. With approximately 60% of revenues from international markets, Edwards benefits from strong geographic diversification in the growing structural heart disease treatment sector.